Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones

Journal of Clinical Investigation

Volumn 106, Issue 10, 2000, Pages 1221-1228

  Chao, Lily ^a   Marcus Samuels, Bernice ^a   Mason, Mark M ^a   Moitra, Jaideep ^b   Vinson, Charles ^b   Arioglu, Elif ^a   Gavrilova, Oksana ^a   Reitman, Marc L ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE; INSULIN; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; ROSIGLITAZONE; THIAZOLIDINE DERIVATIVE; TRIACYLGLYCEROL; TROGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; FATTY ACID OXIDATION; FATTY LIVER; FEMALE; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; HYPOLIPEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; WHITE ADIPOSE TISSUE;

EID: 0033708410     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI11245     Document Type: Article

References (48)

1. Life without white fat: A transgenic mouse
2. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy
3. Leptin and diabetes in lipoatrophic mice
4. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice
5. Mechanism of insulin resistance in A-ZIP/F-1 fatless mice
6. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications
7. Direct antidiabetic effect of leptin through triglyceride depletion of tissues
8. Thiazolidinediones
9. Treatment of insulin resistance with peroxisome proliferator-activated receptor γ agonists
10. A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat
11. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)
12. Cloning of a new member of the peroxisome proliferator-activated receptor gene family from mouse liver
13. mPPAR gamma 2: Tissue-specifc regulator of an adipocyte enhancer
14. Regulation of PPAR gamma gene expression by nutrition and obesity in rodents
15. Peroxisome proliferator-activated receptor gammal expression is induced during cyclic adenosine monophosphate-stimulated differentiation of alveolar type II pneumonocytes
16. The nuclear eicosanoid receptor, PPARgamma, is aberrandy expressed in colonic cancers
17. Skeletal muscle peroxisome proliferator-activated receptor-gamma expression in obesity and non-insulin-dependent diabetes mellitus
18. Roles of PPARs in health and disease
19. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial
20. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor
21. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats
22. Troglitazone action is independent of adipose tissue
23. Torpor in mice is induced by both leptin-dependent and -independent mechanisms
24. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators
25. Identification of a DNA clone to phospho-enolpyruvate carboxykinase (GTP) from rat cytosol. Alterations in phosphoenolpyruvate carboxykinase RNA levels detectable by hybridization
26. Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a
27. [[omega-(Heterocyclylamino)alkoxy]benzyl]-2,4 thiazolidinediones as potent antihyperglycemic agents
28. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group
29. Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone
30. Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight
31. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes
32. Lack of responses to a beta3 adrenergic agonist in lipoatrophic A-ZIP/F-1 mice
33. Specificity of gene expression in adipocytes
34. PPARgamma activation induces the expression of the adipocyte fatty acid binding protein gene in human monocytes
35. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice
36. PPAR gamma is required for placental, cardiac and adipose tissue development
37. PPAR gamma mediates high-fat diet-induced adipocyre hypertrophy and insulin resistance
38. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro
39. Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency
40. Insights inro insulin resistance and type 2 diabetes from knockout mouse models
41. Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: Model for congenital generalized lipodystrophy
42. Rosiglitazone (BRL49653), a PPARgamma-selecrive agonist, causes peroxisome proliferator-like liver effects in obese mice
43. Peroxisome proliferator-activated receptor alpha-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis
44. The pregnane X receptor: A promiscuous xenobiotic receptor that has diverged during evolution
45. Differential activation of peroxisome proliferator-activated receptor- gamma by troglitazone and rosiglitazone
46. A selective peroxisome proliferator-activated receptor-gamma modulator blocks adipocyte differentiation but stimulates glucose uptake in 3T3-L1 adipocytes
47. A peroxisome proliferator-activated receptor gamma ligand inhibits adipoccyre differentiation